Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Ellagic Acid Enhances Antitumor Efficacy of Temozolomide in an in vitro Glioblastoma Model.

Çetin A, Biltekin B.

Turk Neurosurg. 2019 May 17. doi: 10.5137/1019-5149.JTN.26026-19.1. [Epub ahead of print]

2.

Ellagic Acid enhances the Antitumor Efficacy of Bevacizumab in an In Vitro Glioblastoma Model.

Çetin A, Biltekin B, Degirmencioglu S.

World Neurosurg. 2019 Sep 10. pii: S1878-8750(19)32425-8. doi: 10.1016/j.wneu.2019.08.257. [Epub ahead of print]

PMID:
31518741
3.

BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.

Li M, Liang RF, Wang X, Mao Q, Liu YH.

Oncol Lett. 2017 Dec;14(6):6597-6603. doi: 10.3892/ol.2017.7034. Epub 2017 Sep 22.

4.

Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.

Fukai J, Koizumi F, Nakao N.

PLoS One. 2014 Aug 11;9(8):e104538. doi: 10.1371/journal.pone.0104538. eCollection 2014.

5.

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M.

J Neurochem. 2006 Feb;96(3):766-76. Epub 2006 Jan 9.

6.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.

J Natl Cancer Inst. 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2016 May.

7.

Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9. doi: 10.1016/j.ijrobp.2009.04.026.

8.

A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.

Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J.

Cancer Chemother Pharmacol. 2008 Apr;61(4):653-9. Epub 2007 Jun 13.

PMID:
17564708
9.

Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.

Tezcan G, Tunca B, Demirci H, Bekar A, Taskapilioglu MO, Kocaeli H, Egeli U, Cecener G, Tolunay S, Vatan O.

Nutr Cancer. 2017 Aug-Sep;69(6):873-880. doi: 10.1080/01635581.2017.1339810. Epub 2017 Jul 18.

PMID:
28718668
10.

20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.

Chen Z, Wei X, Shen L, Zhu H, Zheng X.

Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.

11.

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.

Vlachostergios PJ, Hatzidaki E, Papandreou CN.

Neurol Res. 2013 Oct;35(8):879-82. doi: 10.1179/1743132813Y.0000000191. Epub 2013 Mar 22.

PMID:
23561593
12.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
13.

Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU.

Li Z, Xia Y, Bu X, Yang D, Yuan Y, Guo X, Zhang G, Wang Z, Jiao J.

Oncol Lett. 2018 Jun;15(6):9877-9883. doi: 10.3892/ol.2018.8551. Epub 2018 Apr 20.

14.
15.

Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.

Pan Q, Yang XJ, Wang HM, Dong XT, Wang W, Li Y, Li JM.

Cell Biochem Biophys. 2012 Jan;62(1):185-91. doi: 10.1007/s12013-011-9280-7.

PMID:
21892781
16.

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG.

J Neurooncol. 2011 Mar;102(1):1-7. doi: 10.1007/s11060-010-0283-9. Epub 2010 Jul 1.

PMID:
20593219
17.
18.

Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis.

Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica G.

Cancer Cell Int. 2018 Sep 10;18:136. doi: 10.1186/s12935-018-0626-8. eCollection 2018.

19.

The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.

Remington M, Chtchetinin J, Ancheta K, Nghiemphu PL, Cloughesy T, Lai A.

Neuro Oncol. 2009 Feb;11(1):22-32. doi: 10.1215/15228517-2008-080. Epub 2008 Sep 23.

20.

Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.

Ciechomska IA, Marciniak MP, Jackl J, Kaminska B.

Front Pharmacol. 2018 Nov 2;9:1271. doi: 10.3389/fphar.2018.01271. eCollection 2018.

Supplemental Content

Support Center